The Integrated Genomic Landscape of Thymic Epithelial Tumors

Milan Radovich, Curtis R. Pickering, Ina Felau, +178

Cancer Cell

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

Anish Thomas, Arun Rajan, Arlene Berman, +15

The Lancet Oncology

Open-label Phase 2OncologyClinical TrialsImmune Checkpoint InhibitorDermatology +4

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan, +15

The Lancet Oncology

MedicineJavelin Solid TumorSolid TumoursMetronomic TherapySurgery +4

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

James L. Gulley, Arun Rajan, David R. Spigel, +11

The Lancet Oncology

OncologyJavelin Solid TumorMetronomic TherapyClinical TrialsBronchial Neoplasm +7

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

Ariel López-Chávez, Anish Thomas, Arun Rajan, +22

Journal of Clinical Oncology

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

Giuseppe Giaccone, Arun Rajan, Arlene Berman, +9

Journal of Clinical Oncology

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Ronan J. Kelly, Anish Thomas, Arun Rajan, +13

Annals of Oncology

Phase I/ii StudyMedicinePharmacologyBronchial NeoplasmSurvivin Suppressor +6

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

Blake M. Warner, Alan N. Baer, Evan J. Lipson, +14

The Oncologist

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Nitin Roper, Anna‐Leigh Brown, Jun S. Wei, +28

Cell Reports Medicine

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors

Anish Thomas, Christophe E. Redon, Linda Sciuto, +21

Journal of Clinical Oncology